Acumen Pharmaceuticals Inc (ABOS) - Total Assets
Based on the latest financial reports, Acumen Pharmaceuticals Inc (ABOS) holds total assets worth $122.83 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ABOS book value for net asset value and shareholders' equity analysis.
Acumen Pharmaceuticals Inc - Total Assets Trend (2019–2025)
This chart illustrates how Acumen Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Acumen Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Acumen Pharmaceuticals Inc's total assets of $122.83 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.0% |
| Accounts Receivable | $625.00K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $29.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Acumen Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Acumen Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Acumen Pharmaceuticals Inc's current assets represent 99.5% of total assets in 2025, an increase from 98.0% in 2019.
- Cash Position: Cash and equivalents constituted 44.0% of total assets in 2025, down from 89.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Acumen Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Acumen Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Acumen Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.07 | 6.46 | 1.35 |
| Quick Ratio | 4.07 | 6.45 | 1.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $92.25 Million | $150.70 Million | $10.92 Million |
Acumen Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Acumen Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.77 |
| Latest Market Cap to Assets Ratio | 1.40 |
| Asset Growth Rate (YoY) | -48.6% |
| Total Assets | $122.83 Million |
| Market Capitalization | $171.87 Million USD |
Valuation Analysis
Above Book Valuation: The market values Acumen Pharmaceuticals Inc's assets above their book value (1.40x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Acumen Pharmaceuticals Inc's assets decreased by 48.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Acumen Pharmaceuticals Inc (2019–2025)
The table below shows the annual total assets of Acumen Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $122.83 Million | -48.60% |
| 2024-12-31 | $238.99 Million | -22.94% |
| 2023-12-31 | $310.12 Million | +57.75% |
| 2022-12-31 | $196.59 Million | -14.65% |
| 2021-12-31 | $230.33 Million | +418.42% |
| 2020-12-31 | $44.43 Million | +506.79% |
| 2019-12-31 | $7.32 Million | -- |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target s… Read more